These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32028905)

  • 1. Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
    Kogo M; Fujimoto D; Hosoya K; Nagata K; Nakagawa A; Tachikawa R; Yamashita D; Kitamura Y; Imai Y; Tomii K
    BMC Cancer; 2020 Feb; 20(1):104. PubMed ID: 32028905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
    Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
    Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
    Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
    Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
    Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests.
    Nakamura H; Koizumi H; Sakai H; Kimura H; Miyazawa T; Marushima H; Saji H; Takagi M
    Clin Lung Cancer; 2018 Mar; 19(2):170-174. PubMed ID: 29150249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
    Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
    Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
    Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
    Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
    Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
    Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
    Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
    Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
    Benlloch S; Botero ML; Beltran-Alamillo J; Mayo C; Gimenez-Capitán A; de Aguirre I; Queralt C; Ramirez JL; Ramón y Cajal S; Klughammer B; Schlegel M; Bordogna W; Chen D; Zhang G; Kovach B; Shieh F; Palma JF; Wu L; Lawrence HJ; Taron M
    PLoS One; 2014; 9(2):e89518. PubMed ID: 24586842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).
    Heeke S; Benzaquen J; Hofman V; Ilié M; Allegra M; Long-Mira E; Lassalle S; Tanga V; Salacroup C; Bonnetaud C; Fayada J; Gazoppi L; Ribeyre L; Castelnau O; Garnier G; Cattet F; Nanni I; de Fraipont F; Cohen C; Berthet JP; Leroy S; Poudenx M; Marquette CH; Denis MG; Barlesi F; Hofman P
    Clin Lung Cancer; 2020 Jan; 21(1):56-65.e8. PubMed ID: 31519454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
    Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
    Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
    Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
    J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
    Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
    APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.